Paper33211112
Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
Cullinane C and 7 others. JAMA Netw Open, 2020. Cited by 119 papers, by iCite.
Cite this record
ConductScience Library. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis. Papers, record 33211112. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33211112
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Circulating Tumor DNA | Major topic |
| Aftercare | |
| Disease-Free Survival | |
| Female | |
| Humans | |
| Neoplasm Metastasis | |
| Neoplasm Recurrence, Local | |
| Neoplasm Staging | |
| Observational Studies as Topic | |
| Precision Medicine | |
| Prognosis | |
| Progression-Free Survival | |
| Prospective Studies | |
| Retrospective Studies |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30588246 | Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer. | J Cancer | 2018 | https://conductscience.org/library/papers/30588246 | PubMed |
| 2 | 30889786 | Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. | J Clin Med | 2019 | https://conductscience.org/library/papers/30889786 | PubMed |
| 3 | 30654364 | Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment. | Oncology | 2019 | https://conductscience.org/library/papers/30654364 | PubMed |
| 4 | 29595655 | The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis. | Medicine (Baltimore) | 2018 | https://conductscience.org/library/papers/29595655 | PubMed |
| 5 | 20652370 | Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. | Eur J Epidemiol | 2010 | https://conductscience.org/library/papers/20652370 | PubMed |
| 6 | 31391323 | Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. | Sci Transl Med | 2019 | https://conductscience.org/library/papers/31391323 | PubMed |
| 7 | 30833418 | Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer. | Cold Spring Harb Mol Case Stud | 2019 | https://conductscience.org/library/papers/30833418 | PubMed |
| 8 | 28392479 | Circulating Tumor DNA as Biomarkers for Cancer Detection. | Genomics Proteomics Bioinformatics | 2017 | https://conductscience.org/library/papers/28392479 | PubMed |
| 9 | 26786933 | Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/26786933 | PubMed |
| 10 | 27532364 | Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. | JAMA Oncol | 2016 | https://conductscience.org/library/papers/27532364 | PubMed |
| 11 | 31241775 | Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. | Int J Cancer | 2020 | https://conductscience.org/library/papers/31241775 | PubMed |
| 12 | 31183188 | Feasibility and clinical value of circulating tumor DNA testing in patients with gastric adenocarcinomas. | J Gastrointest Oncol | 2019 | https://conductscience.org/library/papers/31183188 | PubMed |
| 13 | 15734995 | Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. | Cancer Res | 2005 | https://conductscience.org/library/papers/15734995 | PubMed |
| 14 | 23974828 | The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. | Breast Cancer Res Treat | 2013 | https://conductscience.org/library/papers/23974828 | PubMed |
| 15 | 14633683 | DNA methylation in serum of breast cancer patients: an independent prognostic marker. | Cancer Res | 2003 | https://conductscience.org/library/papers/14633683 | PubMed |
| 16 | 29572011 | Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. | Cancer Genet | 2018 | https://conductscience.org/library/papers/29572011 | PubMed |
| 17 | 27091708 | Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27091708 | PubMed |
| 18 | 12473587 | Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. | Clin Cancer Res | 2002 | https://conductscience.org/library/papers/12473587 | PubMed |
| 19 | 27144417 | The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. | Expert Rev Mol Diagn | 2016 | https://conductscience.org/library/papers/27144417 | PubMed |
| 20 | 25987569 | Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. | EMBO Mol Med | 2015 | https://conductscience.org/library/papers/25987569 | PubMed |
Cited by80
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 119 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42737612 | Circulating Tumor DNA and Circulating Tumor Cells in Liquid Biopsy as Post-Treatment Prognostic Biomarkers in Early Breast Cancer: A Systematic Review and Meta-Analysis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737612 | PubMed |
| 42727049 | Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/42727049 | PubMed |
| 42653691 | Antibody-Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42653691 | PubMed |
| 42455255 | Optimizing Extended Adjuvant Endocrine Therapy in Early HR+/HER2- Breast Cancer: The Emerging Role of Genomic Assays and ctDNA MRD. | Adv Ther | 2026 | https://conductscience.org/library/papers/42455255 | PubMed |
| 42200016 | Predicting the prognosis of breast cancer patients by using nutrition-based index: a systematic review and meta-analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42200016 | PubMed |
| 42003932 | Biological basis and clinical translation prospects of circulating cell-free DNA in precision management of breast cancer (Review). | Oncol Lett | 2026 | https://conductscience.org/library/papers/42003932 | PubMed |
| 41951687 | Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/41951687 | PubMed |
| 41827756 | From Feasibility to Individualization: Surgery for Breast Cancer Liver and Lung Metastases. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41827756 | PubMed |
| 41710655 | Accuracy of ctDNA-based minimal residual disease detection in predicting postoperative recurrence of breast cancer: a meta-analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/41710655 | PubMed |
| 41543393 | ctDNA Detected after Neoadjuvant Therapy for HER2-Positive Breast Cancer Is Associated with Inferior Outcomes and May Inform Adjuvant Therapy. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/41543393 | PubMed |
| 40844552 | The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis. | J Cancer Res Clin Oncol | 2025 | https://conductscience.org/library/papers/40844552 | PubMed |
| 40742511 | Was kommt nach CDK4/6-Inhibition? Perspektiven beim fortgeschrittenen Mammakarzinom. | Wien Klin Wochenschr | 2025 | https://conductscience.org/library/papers/40742511 | PubMed |
| 40681188 | Preoperative partial breast reirradiation and repeat breast-conserving surgery in patients with recurrent breast cancer: the prospective single-arm REPEAT trial - a study protocol. | BMJ Open | 2025 | https://conductscience.org/library/papers/40681188 | PubMed |
| 40586858 | Liquid biopsy in breast cancer: clinical implications of ctDNA and CTCs in diagnosis, treatment and monitoring. | Mol Cell Biochem | 2025 | https://conductscience.org/library/papers/40586858 | PubMed |
| 40428282 | The Application of Circulating Tumour DNA (ctDNA) in the Diagnosis, Prognosis, and Treatment Monitoring of Gynaecological and Breast Cancers (Review). | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/40428282 | PubMed |
| 40295143 | Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40295143 | PubMed |
| 40146490 | Circulating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study. | Ann Surg Oncol | 2025 | https://conductscience.org/library/papers/40146490 | PubMed |
| 40055250 | Development of a prediction model for ctDNA detection (Cir-Predict) in breast cancer. | Breast Cancer Res Treat | 2025 | https://conductscience.org/library/papers/40055250 | PubMed |
| 39896816 | The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. | Front Immunol | 2024 | https://conductscience.org/library/papers/39896816 | PubMed |
| 39844103 | Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis. | BMC Cancer | 2025 | https://conductscience.org/library/papers/39844103 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABL1 | 25 | PubTator's text mining | https://conductscience.org/library/genes/25 | NCBI Gene |
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| CDK12 | 51755 | PubTator's text mining | https://conductscience.org/library/genes/51755 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PIK3CA | 5290 | PubTator's text mining | https://conductscience.org/library/genes/5290 | NCBI Gene |
| RASSF1 | 11186 | PubTator's text mining | https://conductscience.org/library/genes/11186 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33211112
GET https://conductscience.org/api/papers/v1/33211112/references?page=2